MAPK1IP1L::TFE3-rearranged renal cell carcinoma: a novel fusion adding to the differential diagnosis of oncocytic renal neoplasms
- 25.01.2025
- BRIEF REPORT
- Verfasst von
- Anne V. Cheng
- Douglas J. Wu
- Lisa Aviva Friedman
- Emily Chan
- Sean R. Williamson
- Laurence A. Galea
- Ankur R. Sangoi
- Erschienen in
- Virchows Archiv | Ausgabe 4/2025
Abstract
Beyond the more common TFE3 fusion partners PRCC, ASPSCR1, and SFPQ, additional less common fusion partners of TFE3-rearranged renal cell carcinoma (RCC) have been described. Herein, we present an example of TFE3-rearranged renal cell carcinoma harboring fusion partner MAPK1IP1L, a rare rearrangement with only one other reported tumor found in the literature. The currently reported TFE3-rearranged RCC demonstrates unique histological features compared to the previously reported tumor including dense eosinophilic cytoplasm and nuclear pseudoinclusions (corroborated by electron microscopic evaluation), with features not typically seen in other TFE3-rearranged RCCs. Recognizing this novel fusion may be important in the identification, classification, and development of potential therapeutic agents of kidney tumors in the future.
Anzeige
- Titel
- MAPK1IP1L::TFE3-rearranged renal cell carcinoma: a novel fusion adding to the differential diagnosis of oncocytic renal neoplasms
- Verfasst von
-
Anne V. Cheng
Douglas J. Wu
Lisa Aviva Friedman
Emily Chan
Sean R. Williamson
Laurence A. Galea
Ankur R. Sangoi
- Publikationsdatum
- 25.01.2025
- Verlag
- Springer Berlin Heidelberg
- Erschienen in
-
Virchows Archiv / Ausgabe 4/2025
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307 - DOI
- https://doi.org/10.1007/s00428-025-04031-7
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.